Ibrutinib product-specific bioequivalence guidance
Table of contents
This document provides product-specific guidance on the demonstration of the bioequivalence of ibrutinib.
Keywords: Bioequivalence, generics, ibrutinib
Abbreviations:
- BCS Classification: Biopharmaceutics Classification System
- AUC0-t: area under the plasma concentration curve from administration to last observed concentration at time t
- AUC0-72: area under the plasma concentration curve from administration to last observed concentration at 72 hours
- Cmax: maximum plasma concentration
-
List item
Ibrutinib hard capsules 140 mg and film-coated tablets 140, 280, 420 & 560 mg product-specific bioequivalence guidance (PDF/133.52 KB)
Adopted
First published: 27/06/2022
Legal effective date: 01/01/2023
EMA/CHMP/371445/2021 -
List item
Draft ibrutinib hard capsules 140 mg and film-coated tablets 140, 280, 420 & 560 mg product-specific bioequivalence guidance (PDF/126.34 KB)
Draft: consultation closed
First published: 16/12/2021
Consultation dates: 16/12/2021 to 31/03/2022
EMA/CHMP/371445/2021